Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China
PaperCitations, authors & open-access status
Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 51 citations, 2019 year and closed oa status.
51
Citations
2019
Year
closed
OA Status